GlassScriptPhysician profile
Brett S Bilbrey
NPI 1962448589
$11,670.58
in general payments reported to CMS, 2019-2025
48 companies · $2,309 in 2025
The $2,309 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,600 · 2020: $725 · 2021: $1,297 · 2022: $1,710 · 2023: $1,951 · 2024: $2,078 · 2025: $2,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,338.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,539.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,393.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,309.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,254.86 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $677.04 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.31 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $627.90 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $436.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $398.45 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $346.50 | 2021-2025 | |
| Astellas Pharma US INC | $312.98 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $207.84 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $207.55 | 2019-2024 | Trintellix |
| Zyla Life Sciences, INC. | $195.60 | 2019 | |
| Abbott Laboratories | $186.61 | 2019-2025 | Freestyle Libre 3 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Bilbrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.